We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Newsletters » Drug Industry Daily

Our Publications

Please select a publication below.
Drug Industry Daily

Drug Industry Daily Subscribe

Feb. 25, 2021

Vol.: 20
No. 37
  • Headlines

Headlines

Back to Top

Full Issue of Drug Industry Daily

February 25, 2021
View the entire issue. Read More

NIH to Begin Evaluating Moderna Vaccine Modified Against South African Strain

February 25, 2021
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) will soon begin a phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351, which has been tailored to better protect against the virus’ South African mutation. Moderna will also conduct trials of its own. Read More

FDA’s Review of Johnson & Johnson Vaccine Finds It Safe and Effective for Emergency Authorization

February 25, 2021
The FDA has published a briefing document ahead of Friday’s advisory panel meeting showing that agency staff have found the promising, single-shot Johnson & Johnson COVID-19 vaccine safe and effective enough for Emergency Use Authorization (EUA). Read More

In Final Nomination Hearing, Senate Finance Committee Grills Becerra

February 25, 2021
Senate hearings for HHS Secretary nominee Xavier Becerra, California’s attorney general, concluded Wednesday in the Senate Finance Committee, where Becerra was questioned by senators — and at times heatedly by Republican lawmakers — on a range of healthcare issues including drug pricing, drug shortages and intellectual property protections. Read More

Biden Signs Executive Order to Review U.S. Supply Chain

February 25, 2021
President Biden signed an executive order Wednesday mandating a review of the U.S. supply chain for critical goods, including materials needed for manufacturing COVID-19 products — fulfilling a promise he made on the campaign trail. Read More

Appeals Court Hears Arguments Over ‘Skinny Labeling’

February 25, 2021
As Teva Pharmaceuticals tries to convince the full U.S. Court of Appeals for the Federal Circuit to reconsider its earlier judgment that it has to pay $235.5 million in damages to GlaxoSmithKline (GSK) for patent infringement, oral arguments this week left it unclear whether the final decision will be any different. Read More

Gap in Heart Drug Access Still Exists Between Wealthy Countries and Lower-Income Nations, but is Improving

February 25, 2021
While access to cardiovascular drugs in lower-income countries has expanded, a significant gap still exists between access afforded to them and the access enjoyed by higher-income nations when it comes to these medications. Read More

Briefs

February 25, 2021

Meeting Planner

February 25, 2021

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • AstraZeneca

    AstraZeneca Withdraws Imfinzi’s Bladder Cancer Indication

  • CE mark

    Cue Health’s COVID-19 Test Receives CE Mark

  • Sanofi-Regeneron_Logos.png

    Sanofi’s and Regeneron’s Libtayo Wins FDA Approval for NSCLC

  • PerkinElmer logo

    PerkinElmer’s Rapid Point-of-Care COVID-19 Test Cleared in Europe

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing